NCT06402487View on ClinicalTrials.gov

Propionic Acid in Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

September 15, 2024

Study Completion Date

October 9, 2024

Conditions
Multiple Sclerosis
Interventions
DIETARY_SUPPLEMENT

Propionic acid 1000 mg capsule

Patients will be assigned to propionic acid or placebo as add on MS treatment.

DIETARY_SUPPLEMENT

Placebo

Patients will be assigned to propionic acid or placebo as add on MS treatment.

Trial Locations (1)

5020

Salzburger Landeskliniken, Salzburg

All Listed Sponsors
lead

Salzburger Landeskliniken

OTHER